HYAL2 and lung cancer: The promoter of NKX2-1, a lung cancer biomarker involved in lung development [44], was hypermethylated in five patients (Figure S14), as was that of SOX17. Several genes with recurrent promoter hypermethylation and/or nearby intergenic hyperDMRs were also previously shown to be associated with LUAD or LUSC cancer-specific hypermethylation changes, including HYAL2 (in eight patients), AQP1 (in seven patients), XRCC3 (in five patients), RARA (in four patients), SPTBN1 (in three patients), EPAS1 (in three patients), CD34 (in two patients), and CLU (in two patients).